swm Archives - Cambridge Cognition

Guidance for including elderly patients in clinical trials

14 July 2020 / Insights

Insights Back to resource centre 14 July 2020 Guidance for including elderly patients in clinical trials Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines

Guidance for including elderly patients in clinical trials Read More »

Does neuregulin 1 affect executive function in autism spectrum disorder?

14 January 2019 / Insights

Insights Back to resource centre 14 January 2019 Does neuregulin 1 affect executive function in autism spectrum disorder? We caught up with Dr Arvin Haghighatfard to discuss why he chose CANTAB to investigate the effects of neuregulin 1 on executive dysfunction in autism spectrum disorder. Can you tell us more about yourself and your research group?I am Arvin Haghighatfard, geneticist;

Does neuregulin 1 affect executive function in autism spectrum disorder? Read More »

6 tests for assessing cognition in Parkinson’s disease

18 December 2018 / Insights

Insights Back to resource centre 18 December 2018 6 tests for assessing cognition in Parkinson’s disease Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap. Parkinson’s disease is a complex

6 tests for assessing cognition in Parkinson’s disease Read More »

CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairments

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment

25 October 2018 / Insights

Insights Back to resource centre 25 October 2018 CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials. BackgroundDetecting the progression

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment Read More »

6 cognitive tests for research of depression and mood disorders

3 November 2015 / Insights

Insights Back to resource centre 3 November 2015 6 cognitive tests for research of depression and mood disorders Mood disorders affect 5-10% of the adult population in a given year. The most common mood disorders are major depressive disorder, dysthymia, and bipolar disorder. Here we explore the six CANTAB tests for objectively measuring cognitive function in depression. Mood disorders affect

6 cognitive tests for research of depression and mood disorders Read More »